SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors digest recent financial results, with community chatter focused on valuation concerns after a significant run-up. While some bulls remain optimistic about the company's AI prospects and long-term growth, bears point to a high P/E ratio and potential market correction. News of a major investor taking a short position is also contributing to the conversation.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer ($PFE) is trending due to significant trading volume and speculation around potential acquisitions and earnings. Community discussions revolve around Michael Burry's call option positions and Pfizer's ongoing legal battles with Novo Nordisk over Metsera. Some traders anticipate a breakout post-earnings, while others remain skeptical, citing past performance and heavy debt.

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending as investors discuss recent coverage from Stifel and JPMorgan, highlighting the company's potential in lunar infrastructure and space investments amid rising competition with China. The community is weighing the significance of new contracts and upcoming milestones, including the LTV contract and IM-3 mission, while also debating the stock's volatility and short interest.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending due to positive earnings reports and increasing discussion around its partnerships, especially regarding autonomous vehicle technology with companies like NVIDIA and Lucid. The community is actively discussing the potential for robotaxis and the impact on Uber's future profitability, though some express frustration with the stock's price action despite positive news. Some traders are wary of a potential downside setup, while others are aggressively buying calls in anticipation of a significant move upwards leading up to earnings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending due to a sharp decline following confirmatory trial results for its PMO therapies; while the trial missed its primary endpoint, the company highlights COVID-related impacts and plans to discuss a path to traditional approval with the FDA. The community is debating the significance of the trial results, the future of PMO therapies, and the potential impact on the company's valuation, with some viewing the sell-off as an overreaction and a buying opportunity given Sarepta's revenue and pipeline.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid speculation about privacy coins and potential rotation from Bitcoin, with community members pointing to its limited supply and privacy features. Some traders are highlighting ZEC's strong performance relative to other cryptocurrencies and anticipating further gains, while others caution about overbought conditions and potential pullbacks. Discussions include potential price targets, comparisons to Bitcoin, and the upcoming anniversary catalyst.

Norwegian Cruise Line Holdings Ltd. engages in the provision of cruise travel services. It offers cruise experiences for travelers with itineraries in Europe, Asia, Australia, New Zealand, South America, Africa, Canada, Bermuda, Caribbean, Alaska and Hawaii. Its brands include Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises. The company was founded in 1966 and is headquartered in Miami, FL.

Norwegian Cruise Line Holdings Ltd

Norwegian Cruise Line is trending due to a mixed earnings report, beating EPS expectations but falling slightly short on revenue, sparking debate among investors about its valuation. While the company raised its 2025 adjusted EPS guidance and highlighted record revenue, community sentiment is divided, with some questioning the market's negative reaction and others pointing to potential overvaluation or broader market concerns. Community members are also discussing call/put walls and potential market manipulation.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is trending due to a mixed reaction to earnings, initially dropping on EPS and sales misses despite subscriber growth. The community is debating whether the dip presents a buying opportunity, while analysts are adjusting price targets and highlighting both the potential and the risks around valuation and future growth. Commentary suggests a possible short squeeze is in play, but also concern about overall market weakness affecting SPOT.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amid discussions about its upcoming earnings report and potential partnerships, particularly with Novo Nordisk ($NVO). Community members are debating the company's growth prospects, with some highlighting its expansion into new markets and others expressing concern over profitability and insider selling. Analyst ratings are mixed, with some firms setting high price targets while others have a more cautious outlook.

Hut 8 Corp. operates as a Bitcoin miner that focuses on mining. It provides digital asset mining, hosting, and managed infrastructure operation services. The company was founded on January 27, 2023 and is headquartered in Miami, FL.

Hut 8 Corp

Hut 8 Corp is trending due to strong earnings reports and discussions around its transition into AI infrastructure, sparking bullish sentiment. The community is actively debating the company's future prospects in AI and HPC, as well as potential hyperscaler deals. Some investors are comparing HUT to other miners and AI-focused companies, while also considering the impact of Bitcoin's price on its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Absci Corporation (ABSI) Reports Q2 Loss, Misses Revenue Estimates

ABSCI CORP (ABSI) delivered earnings and revenue surprises of -26.32% and -74.44%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

SAB Biotherapeutics (SABS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Absci Corporation (ABSI) Expected to Beat Earnings Estimates: Should You Buy?

ABSCI CORP (ABSI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Beats Q2 Earnings and Revenue Estimates

Amgen (AMGN) delivered earnings and revenue surprises of +14.45% and +3.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates

Syndax (SNDX) delivered earnings and revenue surprises of +17.00% and +30.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?

Coya Therapeutics, Inc. (COYA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape

FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape FDA Approval Race: AI-Powered Innovations Reshape the Healthcare Landscape PR Newswire VANCOUVER, BC, Feb. 11, 2025 USA News...

Is AMD Stock a Buy, Sell, or Hold on HSBC’s Double Downgrade?

AMD stock fell after an analyst slashed his price target and rating on the stock due to Nvidia competition and weak AI GPU demand.

Absci Corp. shares gained over 4% in the previous session, drawing the most retail interest among biotech stocks on Stocktwits after the company announced a strategic partnership with AMD, which includes a $20 million investment pledge from the chipmaker.&nbsp;This investment, structured as a private investment in public equity (PIPE), reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.The collaboration aims to integrate AMD’s high-performance computing capabilities with Absci’s AI-powered de novo antibody design models.&nbsp;The partnership will be showcased at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on Jan. 15, Absci said.Retail engagement on Stocktwits skyrocketed, with message volume surging by 36,900% on Wednesday.&nbsp;Sentiment on the platform for Absi was 'bullish' heading into Friday even as profit-taking set in, as the company revealed another partnership.&nbsp;<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ABSI_sentiment_and_message_volume_Jan_10_premarket_c443462d4e.png" alt="ABSI sentiment and message volume Jan 10 premarket.png" width="1318" height="324"><figcaption>ABSI sentiment and message volume Jan 10 premarket as of 7:50 am ET | source: Stocktwits</figcaption></figure>Absci and Owkin announced they have teamed up to harness their advanced AI platforms to speed up the discovery and design of new medicines. The partnership will focus on creating treatments for cancer and other conditions like immune disorders and inflammation.&nbsp;<stembedurl>https://stocktwits.com/GeraldK75/message/599519367</stembedurl><stembedurl>https://stocktwits.com/J_The_Legend/message/599520163</stembedurl><stembedurl>https://stocktwits.com/GeraldK75/message/599508901</stembedurl>Adding to Wednesday’s optimism, Cathie Wood’s ARK Investment purchased 608,900 Absci shares, through its ARK Genomic Revolution ETF (ARKG), valued at over $1.9 million as of the last close.&nbsp;AI-driven drug discovery is a space being increasingly targeted by major tech players. Last year, Nvidia&nbsp;<a href="https://stocktwits.com/news-articles/markets/5/top-biotech-stocks-with-highest-retail-chatter-in-2024/cJOEinNRjV">invested</a> $50 million in Recursion Pharmaceuticals for similar initiatives.KeyBanc lowered its price target for Absci to $5 from $6&nbsp;on Wednesday but maintained an ‘Overweight’ rating, citing the broader rebound in healthcare technology stocks following Donald Trump’s election.&nbsp;The brokerage said it sees opportunities in companies with strong balance sheets but warned of risks for those with limited profitability.&nbsp;Absci reported $127.1 million in cash and equivalents as of September 30, 2024, down from $145.2 million the previous quarter.Shares of the company remain down over 22% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of scientist hand inoculating an agar plates with bacteria in microbiology lab | Image source: Getty Images

Small-Cap Biotech Absci Draws Heavy Attention On $20M AMD Investment Pledge, Retail's Bullish Despite Pre-Market Dip

The investment reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.

Equity

The investment reportedly marks AMD’s entry into life sciences, leveraging its AI chips for drug discovery.


Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	-$0.20	--	--	N/A
Q2 '25	-$0.21	-$0.24	-15.07%	MISSED
Q1 '25	-$0.22	-$0.21	6.10%	BEAT
Q4 '24	-$0.22	-$0.25	-11.77%	MISSED
Q3 '24	-$0.19	-$0.24	-23.64%	MISSED

ABSI
Absci Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ABSI News

ABSIAbsci Corp